NDAORALTABLETPriority Review
Approved
Jul 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
COLESTID (colestipol hydrochloride) by Pfizer is clinical pharmacology cholesterol is the major, and probably the sole precursor of bile acids. Approved for hypertension. First approved in 1994.
Drug data last refreshed 54m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COLESTID (colestipol hydrochloride) is an oral anion exchange resin that binds bile acids in the intestine, preventing their reabsorption and lowering serum cholesterol levels. It is indicated for hypertension and works by disrupting the enterohepatic circulation of bile acids, forcing increased hepatic oxidation of cholesterol and upregulation of LDL receptors. The drug is a non-systemic, non-absorbable polymer that is not metabolized by digestive enzymes.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential contraction of brand team and shift toward generic management or portfolio optimization.
Mechanism of Action
CLINICAL PHARMACOLOGY Cholesterol is the major, and probably the sole precursor of bile acids. During normal digestion, bile acids are secreted via the bile from the liver and gall bladder into the intestines. Bile acids emulsify the fat and lipid materials present in food, thus facilitating…
Worked on COLESTID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.